Financial Technology

Financial Technology - INDUSTRY NEWS

Share

TMCNet:  Small Cap Stocks To Watch - UPIP, AMRN

[January 11, 2013]

Small Cap Stocks To Watch - UPIP, AMRN

Jan 11, 2013 (M2 PRESSWIRE via COMTEX) -- Unwired Planet (Nasdaq: UPIP) $1.31. Announced Thursday after market close that it has entered into a patent purchase agreement with Ericsson whereby Ericsson will transfer to Unwired Planet 2,185 issued US and international patents and patent applications.
Story continues below ↓

The transferred patents significantly broaden Unwired Planet's Mobile Internet-focused portfolio and include 753 United States issued patents related to 2G, 3G and LTE technologies.

Under the terms of the transaction, Ericsson will also contribute 100 additional patent assets annually to Unwired Planet commencing in 2014 through 2018. Unwired Planet will compensate Ericsson with certain ongoing rights in future revenues generated from the enlarged patent portfolio. Unwired Planet will also grant Ericsson a license to the Company's enlarged patent portfolio.

What They Do: Unwired Planet is the inventor of the mobile Internet and established many of the foundational patented technologies that allow mobile devices to connect to the Internet.

Amarin Corporation (Nasdaq: AMRN) $8.37. Today announced that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/610,217. This application includes claims intended to protect the Vascepa(R) (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. After issuance, Amarin plans to list this patent in the FDA's Orange Book.

The claims in this allowed application cover a method of use relating to Vascepa's MARINE indication. Specifically, the allowed independent claim covers use of highly pure icosapent ethyl, or EPA, including Vascepa, in lowering triglycerides through the daily administration of about 4 capsules, each containing about 900 mg to about 1000 mg of EPA, regardless of EPA purity.

What They Do: Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.

About SmallCapReview Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

[ Back To Financial Technology's Homepage ]